Literature DB >> 31133219

Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: A single-arm feasibility study.

Joanie Mercier1, Mélanie Morin2, Dina Zaki3, Barbara Reichetzer4, Marie-Claude Lemieux5, Samir Khalifé6, Chantale Dumoulin7.   

Abstract

OBJECTIVES: Treatments for genitourinary syndrome of menopause (GSM) may not be suitable for all women, may not be completely effective, and may cause adverse effects. Therefore, there is a need to explore new treatment approaches. The objectives were to evaluate the feasibility of using a pelvic floor muscle training (PFMT) program in postmenopausal women with GSM, and to investigate its effect on symptoms, signs, activities of daily living (ADL), quality of life (QoL) and sexual function. STUDY
DESIGN: Postmenopausal women with GSM participated in a single-arm feasibility study embedded in a randomized controlled trial (RCT) on PFMT for urinary incontinence. This substudy was composed of two pre-intervention evaluations, a 12-week PFMT program and a post-intervention evaluation. MAIN OUTCOME MEASURES: Feasibility was defined as study completion and participation in physiotherapy sessions and in-home exercises. The effects of the PFMT program were assessed by measuring GSM symptoms ('Most Bothersome Symptom' approach, ICIQ-UI SF), GSM signs (Vaginal Health assessment scale), GSM's impact on ADL (Atrophy Symptom questionnaire), QoL and sexual function (ICIQ-VS, ICIQ-FLUTSsex) and leakage episodes.
RESULTS: Thirty-two women participated. The study completion rate was high (91%), as was participation in treatment sessions (96%) and in-home exercises (95%). Post-intervention, there were significant reductions in GSM symptoms and signs (p < 0.01) as well as in its impacts on ADL, QoL and sexual function (p < 0.05).
CONCLUSIONS: A study including a PFMT program is feasible, and the outcomes indicate PFMT to be an effective treatment approach for postmenopausal women with GSM and urinary incontinence. This intervention should be assessed through a RCT.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genitourinary syndrome of menopause; Menopause; Pelvic floor; Physiotherapy; Quality of life; Vaginal atrophy

Mesh:

Year:  2019        PMID: 31133219     DOI: 10.1016/j.maturitas.2019.03.002

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

1.  Turkish day-to-day impact of vaginal aging questionnaire: reliability, validity and relationship with pelvic floor distress.

Authors:  Burcu Sert; Serap Özgül
Journal:  Int Urogynecol J       Date:  2022-01-27       Impact factor: 1.932

2.  Vaginal palpation versus transabdominal ultrasound in the comprehension of pelvic floor muscle contraction after vaginal delivery: a randomised controlled trial.

Authors:  Mayumi Ikeda; Akiko Mori
Journal:  BMC Womens Health       Date:  2021-02-06       Impact factor: 2.809

Review 3.  Effects of Physical Exercise on Sexual Function and Quality of Sexual Life Related to Menopausal Symptoms in Peri- and Postmenopausal Women: A Systematic Review.

Authors:  María Del Carmen Carcelén-Fraile; Agustín Aibar-Almazán; Antonio Martínez-Amat; David Cruz-Díaz; Esther Díaz-Mohedo; María Teresa Redecillas-Peiró; Fidel Hita-Contreras
Journal:  Int J Environ Res Public Health       Date:  2020-04-14       Impact factor: 3.390

Review 4.  Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.

Authors:  Rossella E Nappi; Ellis Martini; Laura Cucinella; Silvia Martella; Lara Tiranini; Alessandra Inzoli; Emanuela Brambilla; David Bosoni; Chiara Cassani; Barbara Gardella
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-21       Impact factor: 5.555

5.  Exercise and Quality of Life in Women with Menopausal Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Thi Mai Nguyen; Thi Thanh Toan Do; Tho Nhi Tran; Jin Hee Kim
Journal:  Int J Environ Res Public Health       Date:  2020-09-26       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.